CytomX Therapeutics Signals Progress in Varseta-M Trial

CytomX Therapeutics Inc. ((CTMX)) has held its Q4 earnings call. Read on for the main highlights of the call.

CytomX Therapeutics’ latest earnings call struck an upbeat tone as management highlighted robust efficacy signals, improving safety, and a clearer path toward registration for Varseta‑M in metastatic colorectal cancer. Executives acknowledged remaining risks, mainly around diarrhea management and the need for larger, more mature datasets, but argued that the positive clinical momentum now clearly outweighs the concerns.

Strong Response Rates Underscore Antitumor Activity

Management emphasized solid antitumor activity for Varseta‑M in late‑line metastatic colorectal cancer, with confirmed objective response rates of 32% at the 10 mg/kg dose and 20% at 8.6 mg/kg. These responses, in heavily pretreated patients, are being positioned as clinically meaningful and supportive of moving toward registrational development.

Progression-Free Survival Trend Continues to Improve

The company reported that preliminary median progression‑free survival has improved from 5.8 months reported in May 2025 to a current range of 6.8–7.1 months. Specifically, median PFS reached 6.8 months at 8.6 mg/kg and 7.1 months at 10 mg/kg, representing an estimated 17%–22% increase versus the prior estimate and reinforcing the durability of benefit.

Enrollment Expansion Builds Clinical Momentum

CytomX highlighted growing momentum in the Phase I program, with total enrollment rising from 73 to 93 patients as of the January 16, 2026 data cut. Of these, 60 patients have been treated at prioritized expansion doses of 7.2, 8.6, and 10 mg/kg every three weeks, supporting both dose optimization and forward planning for pivotal trials.

High EpCAM Expression Validates Target Strategy

The company reported consistently high EpCAM expression across evaluable tumors based on immunohistochemistry, with all H‑scores greater than 200 and the majority at or above 250. This broad and strong expression profile supports EpCAM as a rational target and suggests Varseta‑M could have wide applicability within colorectal cancer populations.

Safety Profile Avoids Historical EpCAM and TOP1 Pitfalls

On safety, management stressed the absence of historical toxicities that have dogged prior EpCAM‑targeted agents, such as pancreatitis and severe liver injury. They also noted no cases of interstitial lung disease, a concern with some TOP1 antibody‑drug conjugates, and reported no dose‑limiting toxicities across the evaluated dose levels.

Dose Optimization Sharply Reduces Severe Diarrhea

A key highlight was a marked reduction in severe diarrhea after introducing adjusted ideal body‑weight dosing and mandatory dual prophylaxis with loperamide and budesonide. In early dose‑optimization cohorts, grade 3 diarrhea fell to 10%, down from 29% in the earlier escalation and expansion phases, equating to a roughly 65% relative decrease from the initial rate.

Durable Disease Control and Extended Treatment Duration

The company underscored durability of benefit, noting median follow‑up exceeding eight months across the study population. At the data cut, 16 patients remained on therapy, with several continuing treatment beyond 11 months, which management presented as evidence of sustained disease control in this late‑line setting.

Favorable Pharmacokinetics Support Masked-PROBODY Design

Pharmacokinetic data were presented as supportive of a favorable therapeutic window, with Varseta‑M showing dose‑proportional exposure and a mean half‑life of roughly six to eight days. Importantly, the drug circulates largely in its masked form, while unconjugated payload CAMP59 remains low at about 1%–3% of total exposure, consistent with the intended PROBODY mechanism.

Clearer Development Roadmap and Near-Term Milestones

CytomX laid out a clearer development path, targeting the start of a registrational study for Varseta‑M in the first half of 2027. Additional dose‑optimization data and details on the pivotal trial design are expected in the second half of 2026, while combination and expansion efforts, including bevacizumab combinations and exploration in other tumors, are already underway.

Diarrhea Persists as Main Adverse Event

Despite improvements, the company acknowledged that diarrhea remains the principal treatment‑related adverse event of interest for Varseta‑M. Grade 3 diarrhea persists at about 10% in early optimization cohorts, compared with 29% in earlier expansion patients, underscoring the continued need for careful management as the program scales.

Electrolyte Disturbances Still Require Vigilant Management

Electrolyte abnormalities, particularly grade 3 hypokalemia, were closely linked to episodes of severe diarrhea and showed reductions in parallel with better prophylaxis. Nonetheless, the company cautioned that managing these imbalances remains an important part of patient care and trial operations as Varseta‑M moves into larger populations.

Early Optimization Cohorts Limit Safety and Efficacy Visibility

Management repeatedly emphasized that dose‑optimization data remain immature, with safety and efficacy summaries based on 20 of a planned 40 patients. As a result, conclusions about long‑term safety patterns, recurrence of grade 3 events, and comparative efficacy versus non‑optimized dosing are still preliminary and will need further validation.

Pharmacokinetic Variability and Drivers Remain Under Study

Investigators observed interpatient pharmacokinetic variability in early cohorts and are evaluating how much adjusted ideal body‑weight dosing can smooth these differences. The team also noted that the relative contribution of optimized dosing versus prophylactic regimens to the improved safety profile is not yet fully quantified and remains an area of active analysis.

Regulatory Path and Endpoints Still Taking Shape

CytomX indicated that overall survival is expected to serve as the primary endpoint for the pivotal Varseta‑M trial, though the final design is still being negotiated. Discussions with regulators are ongoing, and the ultimate trial size, endpoints, and statistical framework will depend on further maturation of survival and other key efficacy data.

Operational Challenges from Rapid Early Enrollment

The company admitted that rapid expansion‑phase enrollment initially outpaced the rollout of standardized loperamide prophylaxis, contributing to higher early rates of diarrhea. Looking forward, management highlighted the need to ensure consistent real‑world adherence to prophylaxis and dosing protocols as Varseta‑M moves toward broader clinical use.

Forward Outlook and Key Development Milestones

Looking ahead, CytomX plans to complete enrollment of 40 patients in the dose‑optimization cohorts to better define the balance between efficacy and safety. With 93 Phase I patients already treated and 16 still on therapy, the company aims to refine pivotal design in 2026 and launch a registrational study in the first half of 2027, positioning Varseta‑M as a potential new option in late‑line colorectal cancer.

CytomX’s call painted a picture of a program gaining clinical traction, with rising response rates, improving progression‑free survival, and a more manageable safety profile. While diarrhea management, data maturity, and regulatory clarity remain key watchpoints, investors heard a largely optimistic narrative that Varseta‑M is progressing toward registrational readiness with tangible near‑term catalysts ahead.